Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

sales@dingminpharma.com

86-311-67260775

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

Alle
  • Alle
  • Titel
Sprache

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd

 [Hebei,China]

Unternehmenstyp:Hersteller , Handels Unternehmen , Händler / Großhändler

Hauptmärkte: Amerikas , Asien , Osteuropa , Europa , Nordeuropa , Ozeanien , Andere Märkte , Westeuropa , Weltweit , Afrika , Karibik , Mittlerer Osten

Exporteur:81% - 90%

Zert:ISO9001, CCC, FDA, MSDS, FCC, REACH, RoHS

Zuhause> Blog> Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

September 03, 2019

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis


FOSTER CITY, Calif.--Jul. 19, 2019--Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.


Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartiswill receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales.


“Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development.


Gilead’s antiviral portfolio includes among the most widely used medicines for the treatment of HIV, hepatitis B and hepatitis C, as well as influenza infection.


früher
nächste
Kontaktiere uns

Author:

Ms. Lily

Email:

sales@dingminpharma.com

Phone/WhatsApp:

+8615933619867

beliebte Produkte
Aktuelles
Pharnex-Jahresende Party in Shijiazhuang

July 03, 2023

Branchen-Nachricheten
FDA genehmigt neue Medikamente für die Parkinson -Krankheit

July 03, 2023

Apatinib PD-1 News

July 03, 2023

Blog News
Azazacitidine was first marketed, only 5.6% lower than the original research

December 20, 2019

Pharmaceutical intermediate manufacture APIs Merchants in China

February 21, 2019

You may also like
Related Categories

Mail an Lieferanten

Fach:
E-Mail-Adresse:
Nachrichten:

Your message must be betwwen 20-8000 characters

Kontaktiere uns

Author:

Ms. Lily

Email:

sales@dingminpharma.com

Phone/WhatsApp:

+8615933619867

beliebte Produkte
Aktuelles
Pharnex-Jahresende Party in Shijiazhuang

July 03, 2023

Branchen-Nachricheten
FDA genehmigt neue Medikamente für die Parkinson -Krankheit

July 03, 2023

Apatinib PD-1 News

July 03, 2023

Blog News
Azazacitidine was first marketed, only 5.6% lower than the original research

December 20, 2019

Pharmaceutical intermediate manufacture APIs Merchants in China

February 21, 2019

Zuhause

Product

Phone

Über uns

Anfrage
Please Leave Us A Message

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

Laden Sie den Anhang hoch
senden